REFERENCES
- Tuynman J. B., Peppelenbosch M. P., Rechel D. J. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 2004; 52: 81–101
- Thun M. J., Henley S. J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–266
- Takahashi T., Kozaki K., Yatabe Y., Achiwa H., Hida T. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 2002; 21: 177–181
- Hase T., Yoshimura R., Matsuyama M., Kawahito Y., Wada S., Tsuchida K., Sano H., Nakatani T. Cyclooxygenase-1 and -2 in human testicular tumours. Eur J Cancer 2003; 39: 2043–2049
- Koki A. T., Masferrer J. L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9: 28–35
- Fujita T., Matsui M., Takaku K., Uetake H., Ichikawa W., Taketo M. M., Suqihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823–4826
- Koehne C. H., DuBois R. N. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31: 12–21
- Nelson W. J., Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483–1487
- Kim P. J., Plescia J., Clevers H., Fearon E. R., Altieri D. C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362: 205–209
- Zhang T., Fields J. Z., Ehrlich S. M., Boman B. M. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 2004; 308: 434–437
- Rice P. L., Kelloff J., Sullivan H., Drigers L. J., Beard K. S., Kuwada S., Piazza G., Ahnen D. J. Sulindac metabolites induce caspase- and proteasome-dependent degradation of betacatenin protein in human colon cancer cells. Mol Cancer Ther 2003; 2: 885–892
- Chen T., Yang I., Irby R., Shain K. H., Wang H. G., Quackenbush J., Coppola D., Cheng J. Q., Yeatman T. J. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res 2003; 63: 4368–4374
- Yao M., Kargman S., Lam E. C., Kelly C. R., Zheng Y., Luk P., Kwong E., Evans J. F., Wolfe M. M. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586–592
- Trifan O. C., Durham W. F., Salazar V. S., Horton J., Levine B. D., Zweifel B. S., Davis T. W., Masferrer J. L. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778–5784
- Bresalier R. S., Sandler R. S., Quan H., Bolognese J. A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstan M. A., Baron J. A. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–1102
- Solomon S. D., McMurray J. J., Pfeffer M. A., Wittes J., Fowler R., Finn P., Anderson W. F., Zauber A., Hawk E., Bertaqnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. N Engl J Med 2005; 352: 1071–1080, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention